Introduction {#s1}
============

Having moved well into the era of personalised medicine, laboratories are being called on to routinely test solid tumours, such a colorectal,[@R1] lung,[@R6] melanoma[@R10] and gastrointestinal stromal tumours (GIST)[@R11] for a variety of biomarkers, which will determine treatment options.

One way to monitor accuracy and reproducibility of testing is through participation in external quality assessment (EQA) schemes. Several studies have demonstrated the benefits of scheme participation,[@R14] having seen an improvement that is, a decrease in genotyping errors, with continuous EQA participation.

The United Kingdom National External Quality Assessment service (UK NEQAS) for Molecular Genetics has been providing EQA schemes for the assessment of colorectal cancer (CRC) (since 2009), lung cancer (since 2010), melanoma (since 2012) and GIST (since 2008). The scheme sends tumour samples to participating laboratories 2--3 times per year and provides an assessment of genotyping, interpretation and clerical accuracy. These molecular pathology EQAs are ISO 17043 (<https://www.iso.org/standard/29366.html>) accredited.

In addition to the samples sent out as part of run 2 of the 2015--16 Molecular Pathology EQA schemes, a manufactured human cell-line reference sample (Thermo Fisher Scientific (AcroMetrix)) was also distributed to laboratories. Here we report on the data gathered from 101 laboratories, who returned genotyping and variant allele frequency results.

Materials and methods {#s2}
=====================

UK NEQAS for Molecular Genetics supplied an educational EQA case using a reference sample as part of the Molecular Pathology 2015--2016 run 2 distributions. One rolled section (10 µm thickness) of formalin-fixed paraffin-embedded (FFPE) cell-line material was provided to each laboratory. This was manufactured by Thermo Fisher Scientific (AcroMetrix), to contain a large number of variants, present at varying frequencies. These frequencies were independently validated by digital droplet PCR prior to distribution.

Laboratories participating in the CRC, lung cancer, melanoma and GIST Molecular Pathology EQA schemes were invited, as a voluntary exercise, to extract DNA from the FFPE section and test using their routine protocols for any of the targets in [table 1](#T1){ref-type="table"}.

###### 

Genes which could be tested for the presence of variants in the reference sample

  -------- ------- ------- -------- --------- ------
  ABL1     EGFR    GNA11   KIT      PDGFRA    VHL
  AKT1     ERBB2   GNAQ    KRAS     PIK3CA    TP53
  ALK      ERBB4   GNAS    MAP2K1   PTEN      
  APC      EZH2    HNF1A   MET      PTPN11    
  ATM      FBXW7   HRAS    MLH1     RB1       
  BRAF     FGFR1   IDH1    MPL      RET       
  CDH1     FGFR2   IDH2    MSH6     SMAD4     
  CDKN2A   FGFR3   JAK2    NOTCH1   SMARCB1   
  CSF1R    FLT3    JAK3    NPM1     SMO       
  CTNNB1   FOXL2   KDR     NRAS     STK11     
  -------- ------- ------- -------- --------- ------

Results were submitted using a supplied *proforma*, which also requested information on test methodology and the percentage variant frequency detected for each variant reported.

No EQA scores were assigned to participating laboratories, and the Scheme subsequently provided these laboratories with a complete breakdown of the validated variant frequencies within each gene, thus allowing the reassessment of raw data, if variants had not been identified by participants.

Results {#s3}
=======

Participation {#s3a}
-------------

One hundred and one laboratories tested this reference sample and submitted results. Several laboratories carried out more than one test methodology and therefore reported multiple results. A total of 2889 test results were reported spanning 53 different genes. There were only 52 different genes in the reference sample; however, one laboratory unexpectedly reported test results for proto-oncogene tyrosine-protein kinase Src (SRC). Known polymorphisms, which accounted for 1.59% of results, were excluded from subsequent analysis. Fifty-eight variants present in the reference sample were incorrectly reported as 'no mutation detected', spread over 17 different genes. The analysis reported here is confined to the seven most commonly tested genes: *KRAS, NRAS, BRAF, EGFR, PIK3CA, KIT* and *PDGFRA* ([figure 1](#F1){ref-type="fig"}).

![Genes tested by participating laboratories.](jclinpath-2018-205277f01){#F1}

Testing methodologies {#s3b}
---------------------

The most commonly used mutation test was by next generation sequencing (NGS), with 48/101 (47.5%) of laboratories returning data using NGS. The percentage of results reported by NGS, compared with single-gene technologies (pyrosequencing, Sanger sequencing, mass spectrometry, real-time PCR, StripAssay, EntroGen mutation kits, Cobas 4800, LightMix Kit) is shown in [table 2](#T2){ref-type="table"}. The Ion Torrent was the preferred NGS platform for the testing of all genes, with the Illumina platform being the second most common. Data provided by participants relating to the panel used were sparse, but most commonly reported was the AmpliSeq for Illumina Cancer Hotspot Panel V.2.

###### 

Percentage of all results submitted which were obtained by NGS

  Gene       Number of results reported by NGS   Percentage of the total number of results reported by NGS (%)
  ---------- ----------------------------------- ---------------------------------------------------------------
  *BRAF*     115                                 56.1
  *EGFR*     298                                 81.4
  *KIT*      143                                 59.1
  *KRAS*     115                                 56.1
  *NRAS*     128                                 59
  *PDGFRA*   84                                  92.3
  *PIK3CA*   230                                 94.3

NGS, next generation sequencing.

Variants and variant allele frequencies {#s3c}
---------------------------------------

The number of validated variants within each of the seven most commonly tested genes is shown in [table 3](#T3){ref-type="table"}, along with the mean validated frequency. Digital droplet PCR was used by Thermo Fisher to independently validate the variant frequencies within the reference samples prior to distribution. Multiple measurements were taken and an average result determined.

###### 

Validated variant numbers and frequencies within the seven most commonly reported genes

  Gene       Number of variants present   Mean variant frequency (%)
  ---------- ---------------------------- ----------------------------
  *BRAF*     8                            2.6
  *EGFR*     27                           2.6
  *KIT*      24                           4.2
  *KRAS*     8                            4.3
  *NRAS*     5                            7.4
  *PDGFRA*   8                            4.2
  *PIK3CA*   24                           4.7

In terms of the correct reporting of all variants in each gene, only eight laboratories reported all five variants present in *NRAS* and two laboratories correctly identified all of the eight variants in *BRAF*. No laboratories correctly reported all the variants present in any of the other genes. There were in fact several laboratories who failed to report the presence of any variants in the seven most commonly reported genes and returned a wild type (WT) result. These are detailed in [table 4](#T4){ref-type="table"}.

###### 

The number of laboratories incorrectly reporting a WT result

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       Mean variant frequency (%)   Number of laboratories reporting WT result   Number of tests performed with no variants reported   Methodologies employed (n)
  ---------- ---------------------------- -------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------
  *BRAF*     2.6                          21                                           22                                                    Sanger (4),\
                                                                                                                                             Pyrosequencing (4),\
                                                                                                                                             Cobas 4800 (5),\
                                                                                                                                             RT-PCR (2),\
                                                                                                                                             HRM (2)\*

  *EGFR*     2.6                          3                                            6                                                     Sanger (1), Pyrosequencing (1),\
                                                                                                                                             NGS/Ion Torrent (2), RT-PCR (1)

  *KIT*      4.2                          1                                            1                                                     Sanger (1)

  *KRAS*     4.3                          7                                            9                                                     Sanger (4), Pyrosequencing (2), NGS/Ion Torrent (1), RT-PCR (1),\
                                                                                                                                             Entrogen (1)

  *NRAS*     7.4                          3                                            5                                                     Sanger† (2), Pyrosequencing (2),\
                                                                                                                                             NGS/Ion Torrent (1)

  *PDGFRA*   4.2                          1                                            1                                                     Sanger (1)

  *PIK3CA*   4.7                          1                                            2                                                     Pyrosequencing (1),\
                                                                                                                                             NGS/Ion Torrent (1)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*In addition to those listed in the table, one laboratory used Therascreen, one laboratory used Amoy Dx BRAF Mutation Detection kit, one laboratory used Idylla, one laboratory performed NGS on an Ion Torrent platform and one laboratory did not disclose the NGS methodology used.

†Sanger sequencing.

WT, wild type.

More variants were engineered into the reference sample than are clinically actionable, which may account for the differences seen in variant reporting. The most commonly reported variant in each gene is shown in [table 5](#T5){ref-type="table"}, along with the clinically relevant variants engineered into the sample.

###### 

Most commonly reported variants in each gene and clinically relevant mutations

  Gene       Most commonly reported variant by participants   Clinically relevant variants known to be present in the sample
  ---------- ------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------
  *BRAF*     c.1799T\>A p.(Val600Glu)                         c.1799T\>A p.(Val600Glu)
  *EGFR*     c.2235_2249del p.(Glu746_Ala750del)              c.2156G\>C p.(Gly719Ala); c.2235_2249del p.(Glu746_Ala750del); c.2573T\>G p.(Leu858Arg) and c.2582T\>A p.(Leu861Gln)
  *KIT*      c.1727T\>C p.(Leu576Asn)                         c.1504_1509dup p.(Ala502_Tyr503dup) and c.1727T\>C p.(Leu576Asn)
  *KRAS*     c.35G\>A p.(Gly12Asp)                            c.35G\>A p.(Gly12Asp), c.175G\>A p.(Ala59Thr) c.183A\>C p.(Gln61His) and c.351A\>C p.(Lys117Asn)
  *NRAS*     c.35G\>A p.(Gly12Asp)                            c.35G\>A p.(Gly12Asp) and c.182A\>G p.(Gln61Arg)
  *PDGFRA*   c.1698_1712del and c.2525A\>T p.(Asp842Val)      c.2525A\>T p.(Asp842Val)
  *PIK3CA*   c.3140A\>G p.(His1047Arg)                        c.1624G\>A p.(Glu542Lys); c.1633G\>A p.(Glu545Lys) and c.3140A\>G p.(His1047Arg)

For *NRAS*, 46/63 (73%) and 44/63 (69.8%) of laboratories, respectively, correctly detected the two clinically relevant variants; c.35G\>A and c.182A\>G. There were four clinically relevant variants in *KRAS* (see [table 5](#T5){ref-type="table"}) and these were identified by 47/68 (69.1%), 25/68 (36.8%), 37/68 (54.4%) and 28/68 (41.2%) laboratories, respectively.

The reference sample included the four most common *EGFR* mutations associated with sensitivity to EGFR receptor tyrosine kinase inhibitors (TKIs): c.2156G\>C, c.2235_2249del, c.2573T\>G and c.2582T\>A. These were correctly reported by 24/59 (40.7%), 50/59 (84.7%), 26/59 (44.1%) and 22/59 (37.3%) laboratories, respectively. Two laboratories reported unexpected variants, using the Ion Torrent AmpliSeq in-house gene panel and an Illumina MiSeq custom panel.

The c.1799T\>A mutation is the most common *BRAF* variant in melanoma and colorectal tumours, and so would be expected to be included in testing panels. Thirty-two of the 53 laboratories (60.4%) correctly reported the detection of this variant. Surprisingly, 39.6% of laboratories failed to do so.

Exons 10 and 21 are known *PIK3CA* mutation hotspots, and 3 of the 24 variants in the reference sample are contained within these exons (see [table 5](#T5){ref-type="table"}). Of the 31 laboratories reporting a result for *PIK3CA* gene variant testing, the variant were correctly identified by 17/31 (54.8%), 18/31 (58.1%) and 26/319 (83.9%) laboratories (respectively). Two laboratories, both using the Qiagen GeneRead Clinically Relevant Mutations panel run on an Illumina MiSeq NGS platform, reported unexpected variants in *PIK3CA*. These were not reported by any other laboratory.

The *KIT* gene variants within exons 9 and 11, including c.1504_1509dup and c.1727T\>A were correctly identified by 17/25 (68%) and 18/25 (72%) laboratories, respectively. Two laboratories reported unexpected variants using the Ion Torrent AmpliSeq inhouse panel and the Illumina MiSeq with the Qiagen GeneRead Clinically relevant mutations panel.

For *PDGFRA*, the most commonly reported mutation was c.2525A\>T, which confers resistance to TKIs. This was identified by 14/21 (66.7%) laboratories, along with c.1698_1712del1712, also by 14/21 (66.7%) laboratories.

Accuracy of testing for the presence of variants {#s3d}
------------------------------------------------

As each laboratory was required to report the percentage variant frequency, it was possible to calculate a mean and median result for each gene. For the purposes of this analysis, the reported frequencies have been grouped by gene, and thus a range for mean and median is shown ([table 6](#T6){ref-type="table"}). As can be clearly seen, laboratories consistently overestimated the variant allele frequency, particularly for variants in *PIK3CA, KIT* and *PDGFRA. BRAF* was the most accurately reported, in terms of mean and median frequencies. When the test methodology was taken into account, less variation was observed in single-gene testing, as opposed to NGS platforms ([figure 2](#F2){ref-type="fig"}), but nonetheless, there was still an overestimation.

###### 

Calculated mean and median variant frequencies, from data submitted by each laboratory

  Gene       Validated mean variant frequency (%)   Range of participant reported mean variant frequencies (%)   Range of participant reported median variant frequencies (%)
  ---------- -------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------
  *BRAF*     2.6                                    4.13--8.21                                                   4.10--5.00
  *EGFR*     2.6                                    3.62--8.84                                                   4.00--7.59
  *KIT*      4.2                                    7.00--17.00                                                  5.99--17.40
  *KRAS*     4.3                                    5.71--10.55                                                  6.06--9.09
  *NRAS*     7.4                                    11.85--16.16                                                 11.43--15.74
  *PDGFRA*   4.2                                    9.37--15.00                                                  8.18--11.22
  *PIK3CA*   4.7                                    10.00--17.80                                                 9.41--17.00

![Variant frequencies reported by participating laboratories, using NGS platforms. The bars represent the percentage variation (+/--) from the validated test allelic frequency. Bars are grouped and coloured by test method. Left panel, non-NGS methodologies; Right panel, NGS methodologies. NGS, next generation sequencing.](jclinpath-2018-205277f02){#F2}

Discussion {#s4}
==========

With the concept of personalised medicine expanding rapidly into practice and biomarker screening becoming routine on many laboratories, it is more important than ever that laboratories reporting these results can demonstrate high quality, accurate validated assays. As results from biomarker screening often determine patient treatment, there must be a high degree of confidence in the assay delivery.

One way that laboratories can demonstrate this is through participation in an EQA scheme, such as those developed, administered and regularly provided by UK NEQAS. In addition to the biannual EQA samples distributed through the CRC, GIST, lung cancer and melanoma schemes, laboratories also received an educational manufactured human cell-line reference sample. A complete set of validated variant and corresponding frequencies was provided to each participating laboratory following result submission to UK NEQAS.

It was reassuring to see that for the most part, the most frequently reported variants were those with clinical relevance. In terms of the variants of relevance to CRC, over two-thirds of laboratories reported the two mutations in *NRAS*, and between 36.8% and 69% correctly identified the clinically relevant variants in *KRAS*. The variant allele frequency of the *NRAS* variants was 7.4%, compared with 4.3% for the *KRAS* variants, which may have explained the lower level of detection for the latter gene variants. Furthermore, slightly more laboratories used NGS for the detection of *NRAS* mutations, compared with *KRAS*, possibly providing an overall lower limit of detection. We must not exclude the possibility that some laboratories do not report mutant allele frequencies below 5%, and thus did detect, but did not report the *KRAS* variants, which they may have found below their lower limit for reporting. Laboratories were encouraged to review their raw data following release of the validated variant data.

Sixty per cent of laboratories correctly identified the common c.1799T\>A p.(V600E) mutation in *BRAF*, in spite of the manufactured variant allele frequency being stated as 2.6%. In CRC screening, *BRAF* is likely to be included in gene panels due to the poor prognosis that this codon 600 mutation confers, and its association with microsatellite instability, both of which will be assessed as part of Lynch Screening (<https://www.nice.org.uk/guidance/dg27>). In melanoma, the presence of this mutation is indicative of response to anti-EGFR therapy.

The four clinically relevant variants in *EGFR* were identified by very differing percentages of participating laboratories, ranging from 37.3% for c.2582T\>A p. (Leu861Gln), up to 84.7% for c.2235_2249del p.(Glu746_Ala750del). This may again be as a result of the very low mean variant allele frequency (2.6%) resulting in laboratories not reporting low level mutations, but the clinical importance of correct mutation identification should be highlighted, as patients whose non-small-cell lung cancers contains such mutations, will fail to respond to TKIs.

Mutation screening of GIST tumours is complex as these tumours arise as a result of a driver mutation in either *KIT* of *PRGFRA*. In addition, there are multiple mutation types, making these tumours difficult to accurately screen. Reassuringly, two thirds of laboratories correctly identified the activating mutation in exon 18 of *PDGFRA*, which confers resistance to TKIs, and again over two thirds correctly identified activating mutations in *KIT.*

Overall, the fact that clinically relevant and actionable variants were reported most frequently, provides reassuring evidence that gene tests have been optimised to detect the majority of clinical important variants in most laboratories.

There were several laboratories which failed to identify any variants in the sample and reported it as WT. With the exception of *KIT* gene testing, Sanger Sequencing was reported as the testing methodology for each gene in at least one laboratory. It is widely acknowledged that the limit of detection for Sanger Sequencing[@R19] is 20%--25% mutant allele frequency in a WT allele background, which may explain the failure to detect the variants presence at lower levels.

Twenty-one laboratories did not detect a variant in the *BRAF* gene. There was huge variation in the testing methodologies used and this perhaps demonstrates reduced access to a more sensitive NGS-based tests for variant detection for this gene. *KRAS* was the next most common gene to be reported as WT (by seven laboratories). The Scheme has seen a large increase in laboratories participating for the first time with limited biomarker molecular testing experience. There is a possibility that such laboratories have limited access to high sensitivity sequencing platforms.

We cannot ignore the engineered artificial nature of the sample, as a contributing factor when it comes to incorrect variant detection. Samples usually received as part of the standard EQA schemes are also FFPE in nature, but consist of a single human tumour sample, rather than an engineered FFPE cell-line. Furthermore, as the reference sample consisted of a single tissue FFPE curl, this would not have been a standard sample format for many participating laboratories and thus added in an additional variable to standard sample processing pipelines.

Increasingly, laboratories are being expected to obtain molecular test results from small and often challenging biopsy samples. To meet these challenges, these laboratories must ensure that their assay design has been fully optimised and that the scope of gene testing is sufficient to meet the requirements of the tests.

Having the ability to test samples such as this reference sample and receive the full genotyping results from UK NEQAS should provide high quality validation information and alert laboratories to any suboptimal assays. This should guide reoptimisation to ensure high quality sample screening.

###### Take home messages

-   Laboratories carrying out mutation screening must maximise opportunities to enrol in External Quality Assurance schemes.

-   Provision of the complete mutation profile of the reference sample to laboratories has allowed, where required, assay optimisation procedures to be undertaken.

-   Schemes such as those run by UK NEQAS offer samples for testing and educational support, which must not be overlooked and should be embraced.
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